ganaxolone
Marinus Pharmaceuticals Cuts 45% of Workforce Following Clinical Setbacks
Marinus Pharmaceuticals, layoffs, workforce reduction, clinical setbacks, ganaxolone, seizures, tuberous sclerosis complex (TSC), refractory status epilepticus (RSE)